US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% META $728.08 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00% NVDA $233.95 ▲+0.00% JNJ $256.03 ▲+0.00% SNDK $1,719.99 ▲+0.00%
FinancialContent

Articles published by Surface Oncology, Inc.

News headline image
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
From Surface Oncology, Inc.
Via GlobeNewswire
Tickers CHRS SURF
News headline image
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023
From Surface Oncology, Inc.
Via GlobeNewswire
Tickers SURF
News headline image
Coherus to Acquire Surface Oncology
From Surface Oncology, Inc.
Via GlobeNewswire
Tickers CHRS SURF
News headline image
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023
From Surface Oncology, Inc.
Via GlobeNewswire
Tickers SURF
News headline image
Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023
From Surface Oncology, Inc.
Via GlobeNewswire
Tickers SURF
News headline image
Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023
From Surface Oncology, Inc.
Via GlobeNewswire
Tickers SURF
News headline image
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022
From Surface Oncology, Inc.
Via GlobeNewswire
Tickers SURF
News headline image
Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference
From Surface Oncology, Inc.
Via GlobeNewswire
Tickers SURF
News headline image
Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference
From Surface Oncology, Inc.
Via GlobeNewswire
Tickers SURF
News headline image
Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors
From Surface Oncology, Inc.
Via GlobeNewswire
Tickers SURF
News headline image
Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting
From Surface Oncology, Inc.
Via GlobeNewswire
Tickers SURF
News headline image
Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort
From Surface Oncology, Inc.
Via GlobeNewswire
Tickers SURF
News headline image
VIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388
From Surface Oncology, Inc.
Via GlobeNewswire
Tickers SURF